Document Detail

Beta3-adrenoreceptor stimulation ameliorates myocardial ischemia-reperfusion injury via endothelial nitric oxide synthase and neuronal nitric oxide synthase activation.
MedLine Citation:
PMID:  22152956     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: This paper examined whether nebivolol protects the heart via nitric oxide (NO) synthase and NO-dependent signaling in an in vivo model of acute myocardial infarction.
BACKGROUND: Beta(3)-adrenergic receptor (AR) activation promotes endothelial nitric oxide synthase (eNOS) activity and NO bioavailability. We hypothesized that specific beta(3)-AR agonists would attenuate myocardial ischemia-reperfusion (MI/R) injury via eNOS activation and increased NO bioavailability.
METHODS: Mice were subjected to 45 min of myocardial ischemia in vivo followed by 24 h of reperfusion (R). Nebivolol (500 ng/kg), CL 316243 (1 μg/kg), BRL-37344 (1 μg/kg), or vehicle (VEH) was administered at the time of R. Myocardial area-at-risk (AAR) and infarct size (INF)/AAR was measured at 24 h of R. Cardiac tissue and plasma were collected to evaluate eNOS phosphorylation, neuronal nitric oxide synthase (nNOS), inducible nitric oxide synthase expression, and nitrite and nitrosothiol levels.
RESULTS: Nebivolol (500 ng/kg) reduced INF/AAR by 37% (p < 0.001 vs. VEH) and serum troponin-I levels from 41 ± 4 ng/ml to 25 ± 4 ng/ml (p < 0.05 vs. VEH). CL 316243 and BRL-37344 reduced INF by 39% and 42%, respectively (p < 0.001 vs. VEH). Nebivolol and CL 316243 increased eNOS phosphorylation at Ser-1177 (p < 0.05 vs. VEH) and increased nitrite and total nitrosylated protein levels. Nebivolol and CL 316243 significantly increased myocardial nNOS expression. Nebivolol failed to reduce INF after MI/R in beta(3)-AR (-/-), eNOS(-/-), and in nNOS(-/-) mice.
CONCLUSIONS: Our results indicate that beta(3)-AR agonists protect against MI/R injury. Furthermore, the cardioprotective effects of beta(3)-AR agonists are mediated by rapid eNOS and nNOS activation and increased NO bioavailability.
Juan P Aragón; Marah E Condit; Shashi Bhushan; Benjamin L Predmore; Sandeep S Patel; D Bennett Grinsfelder; Susheel Gundewar; Saurabh Jha; John W Calvert; Lili A Barouch; Madhav Lavu; Harold M Wright; David J Lefer
Related Documents :
14988626 - Clinical trials in the surgical management of congestive heart failure: surgical ventri...
9654396 - Experimental cardiomyopathy as a model of chronic heart failure.
8656236 - Maximizing therapy in the advanced heart failure patient.
12445536 - Impact of heart failure and left ventricular systolic dysfunction on quality of life: a...
17158246 - Acute volume overload elevates t-wave alternans magnitude.
19523266 - Functional state following the fontan procedure.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  58     ISSN:  1558-3597     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-12-14     Completed Date:  2012-05-11     Revised Date:  2013-06-27    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2683-91     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Department of Surgery, Division of Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, Georgia 30308, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-1 Receptor Antagonists / pharmacology*
Benzopyrans / pharmacology*
Biological Availability
Disease Models, Animal
Ethanolamines / pharmacology*
Mice, Inbred C57BL
Myocardial Reperfusion Injury / enzymology*
Nitric Oxide Synthase Type I / metabolism*
Nitric Oxide Synthase Type III / metabolism*
Receptors, Adrenergic, beta-3 / drug effects*
Grant Support
1R01HL093579-01/HL/NHLBI NIH HHS; 2R01HL-060849-09/HL/NHLBI NIH HHS; 5R01HL-092141-01/HL/NHLBI NIH HHS; 5R01HL098481-02/HL/NHLBI NIH HHS; R01 HL092141-03/HL/NHLBI NIH HHS; R01 HL093579-03/HL/NHLBI NIH HHS; R01 HL098481/HL/NHLBI NIH HHS
Reg. No./Substance:
0/Adrenergic beta-1 Receptor Antagonists; 0/Benzopyrans; 0/Ethanolamines; 0/Receptors, Adrenergic, beta-3; 030Y90569U/nebivolol; EC Oxide Synthase Type I; EC Oxide Synthase Type III
Comment In:
J Am Coll Cardiol. 2011 Dec 13;58(25):2692-4   [PMID:  22152957 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Genetic susceptibility to coronary heart disease in type 2 diabetes: 3 independent studies.
Next Document:  Influence of Diabetes Mellitus on Clinical Outcomes Following Primary Percutaneous Coronary Interven...